The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: Maybe sticking with TTR and following up on the APOLLO-B question, recognizing all the details are not yet. Can you just remind
me whether you plan to take an interim in cardio transform? And maybe talk about whether or how you see the APOLLO-B results
affecting that decision if it is sort of up to you to whether to take an interim? And then second, I think you mentioned planning
additional studies for eplontersen. Can you talk in a little bit more detail about what those might include.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 09, 2022 / 3:30PM, IONS.OQ - Q2 2022 Ionis Pharmaceuticals Inc Earnings Call
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: And on the additional eplontersen trials you alluded to?
Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst
: The first one is just a clarification question for you, Brett. You said that the IgAN data for the Factor B inhibitor was the best you've
seen thus far. Was that targeting just Factor B? Or is that relevant to the complement space more broadly?
And the second question is on the GOLDEN study in geographic atrophy in clinicaltrials.gov has that ending in October 2022. I'm
just wondering whether we expect top line data disclosure in the second half because it's not in your press release.
Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst
: Okay. Beautiful. And just a very, very quick clarification again that IgAN comment includes data from the endothelin receptor
antagonist class that's inclusive of everything.
Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst
: So on olezarsen, with enrollment completed in FCS, remind us about the duration of the study. So will you have data more likely in
the first half or second half of next year? And what should our expectations be with the data, what you're looking for? And what sort
of read-through, if any, might there be for the high trigs study once we see the FCS data. Then I have a couple of follow-ups.
Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst
: Yes. First on that, so you're starting the second (inaudible) Phase III study. So is that going to be the same design and scope as the
first one? And I mean, anything you can do to accelerate enrollment for these studies if you have the resources to do that? Is that a
possibility?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 09, 2022 / 3:30PM, IONS.OQ - Q2 2022 Ionis Pharmaceuticals Inc Earnings Call
Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst
: Yes, yes. And then just one last one, eplontersen and PN. So after you file in the U.S., are you expecting a priority review? And then
just maybe a few details on you and AstraZeneca just in terms of the plans for the launch. Any idea yet about sizing of the sales force?
Any initial conversations with payers? If you said this, I missed it, I apologize. But maybe just run through some of the key activities
as you're prepping to that.
| 
